Mendus
Mendus AB is a clinical-stage Swedish biopharmaceutical enterprise headquartered in Stockholm, Sweden. The company specializes in the development of immunotherapies focused on targeting cancer recurrence and improving treatment outcomes for various oncological indications, including acute myeloid leukemia and ovarian cancer. Its proprietary product pipeline leverages cellular immunotherapy technologies. Principal revenue is currently earned through research grants, development collaborations, and capital financing arrangements as clinical trials advance. Mendus AB is publicly listed on Nasdaq Stockholm.
2 of the funds FundTelligence covers report a position in Mendus.
- Legal name
- Mendus AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Mendus
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)